Get the Stockscreener App
5.03
1.57%
-0.08
Recursion Pharmaceuticals Inc stock is traded at $5.03, with a volume of 32.00M.
It is down -1.57% in the last 24 hours and up +10.55% over the past month.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
See More
Previous Close:
$5.11
Open:
$5.23
24h Volume:
32.00M
Relative Volume:
1.40
Market Cap:
$2.22B
Revenue:
$64.60M
Net Income/Loss:
$-377.75M
P/E Ratio:
-3.2452
EPS:
-1.55
Net Cash Flow:
$-335.64M
1W Performance:
+2.24%
1M Performance:
+10.55%
6M Performance:
-16.58%
1Y Performance:
-45.03%
1-Day Range:
$4.90
$5.355
1-Week Range:
$4.78
$5.355
52-Week Range:
$3.79
$12.36
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Name
Recursion Pharmaceuticals Inc
Sector
Industry
Phone
(385) 269-0203
Address
41S RIO GRANDE STREET, SALT LAKE CITY
Compare RXRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
5.03 | 2.22B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.87 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
509.72 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
309.70 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.15 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
247.08 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-22-23 | Initiated | Morgan Stanley | Equal-Weight |
| Mar-16-23 | Initiated | Needham | Buy |
| Sep-16-22 | Initiated | KeyBanc Capital Markets | Overweight |
| Apr-18-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-04-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-21 | Initiated | Berenberg | Buy |
| May-11-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Goldman | Neutral |
| May-11-21 | Initiated | JP Morgan | Neutral |
| May-11-21 | Initiated | KeyBanc Capital Markets | Overweight |
| May-11-21 | Initiated | SVB Leerink | Outperform |
View All
Recursion Pharmaceuticals Inc Stock (RXRX) Latest News
Recursion Pharmaceuticals stockholders elect three Class I directors - Investing.com Australia
Recursion Pharmaceuticals stockholders elect three Class I directors By Investing.com - Investing.com India
Recursion Pharmaceuticals Holds Annual Stockholder Meeting - TipRanks
Expert Outlook: Recursion Pharmaceuticals Through The Eyes Of 4 Analysts - Benzinga
Recursion Pharmaceuticals (RXRX): Morgan Stanley Adjusts Price Target | RXRX Stock News - GuruFocus
Layoff Tracker: Gilead Cuts 36 Employees in California - BioSpace
Recursion Pharma to reduce workforce by 20% - MSN
Why Recursion Pharmaceuticals Stock Is Plummeting Today - AOL.com
Recursion Pharmaceuticals price target lowered to $5 by Morgan Stanley - Investing.com Canada
Recursion Pharmaceuticals price target lowered to $5 from $8 at Morgan Stanley - TipRanks
Morgan Stanley Cuts Recursion Pharmaceuticals Price Target to $5 From $8, Maintains Equalweight Rating - MarketScreener
Is This Beaten-Down Cathie Wood Artificial Intelligence (AI) Stock a Buy? - MSN
Why Recursion Pharmaceuticals RXRX Could Be the NVDA of Biotech for NASDAQ:RXRX by TopgOptions - TradingView
Recursion to lay off 20% of workforce, narrows focus amid biotech downturn - MSN
Recursion Q1 2025 slides: AI platform advances pipeline amid earnings miss By Investing.com - Investing.com South Africa
Recursion Q1 2025 slides: AI platform advances pipeline amid earnings miss - Investing.com
Cautious Outlook on Recursion Pharmaceuticals Amid Strategic Restructuring and Cash Management Challenges - TipRanks
Insmed surges on lung drug data; Recursion cuts staff - Yahoo Finance
Why Skyrocketed Recursion Pharmaceuticals, Inc. (RXRX) Today - MSN
Recursion: Lack Of Near-Term Catalysts Leaves The Stock Vulnerable (NASDAQ:RXRX) - Seeking Alpha
Recursion Pharmaceuticals (RXRX) Jumps 31% On Next-Gen AI - MSN
Recursion to lay off 20% of workforce amid biotech funding woes - MSN
Why Recursion Pharmaceuticals Was Bouncing Higher on Tuesday - MSN
After pipeline cull, AI drug developer Recursion cuts staff by 20% - FirstWord Pharma
Recursion Eliminating 20% of Workforce, Citing Pipeline Pruning and Capital Markets - Genetic Engineering and Biotechnology News
Recursion Pharmaceuticals Stock Surges After Company Lays Off 20% Workforce: Retail Predicts ‘Blue Skies’ Ahead - MSN
Recursion Pharmaceuticals Stock Is Up 10% Today: What's Happening? - Benzinga
Recursion Downsizes by 20% To Boost Cash Position - BioSpace
Recursion lays off 20% of staff in wake of pipeline cutbacks - Fierce Biotech
Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday - marketscreener.com
Recursion Pharmaceuticals: Recent Readouts Disappointing, Future Readouts Risky (RXRX) - Seeking Alpha
Recursion Cuts 20% of Workforce, Extends Cash Runway to Late 2027 - MarketScreener
Recursion Pharma to reduce workforce by 20% (RXRX:NASDAQ) - Seeking Alpha
Recursion Pharmaceuticals Stock (RXRX): AI Breakthrough for Drug Development - Value The Markets
Recursion Pharmaceuticals (RXRX) Implements Workforce and Operat - GuruFocus
Recursion Pharmaceuticals Announces Workforce Reduction Strategy - TipRanks
Recursion Pharmaceuticals announces 20% workforce reduction - TipRanks
Recursion Pharmaceuticals Announces Personnel And Infrastructure ReductionSEC Filing - marketscreener.com
15 Stocks That Stole The Show Last Week - Insider Monkey
Recursion rises on launch of Boltz-2 in partnership with MIT - MSN
Why Recursion Pharmaceuticals (RXRX) Soared On Friday - Insider Monkey
10 Stocks Are Dominating Like Wall Street Titans - Insider Monkey
Recursion Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:RXRX - Benzinga
Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas - mx.advfn.com
Recursion Pharmaceuticals Stock Surges On Breakthrough AI Model Launch With MIT - Benzinga
Recursion Pharmaceuticals shares surge on AI model release By Investing.com - Investing.com South Africa
Recursion Pharmaceuticals shares surge on AI model release - Investing.com
Recursion Pharmaceuticals call volume above normal and directionally bullish - TipRanks
Recursion Pharmaceuticals (RXRX) Sees Surge in Bullish Options Activity | RXRX Stock News - GuruFocus
Recursion (RXRX) Shares Jump on New Biomolecular Model Launch - GuruFocus
Recursion Pharmaceuticals Inc Stock (RXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.86%
1.98%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):